Workflow
复宏汉霖：HLX13一线治疗不可切除的肝细胞癌(HCC)患者的1期临床试验申请获美国FDA批准
Shanghai HenliusShanghai Henlius(HK:02696) Zhi Tong Cai Jing·2025-09-29 09:24

Core Viewpoint - The company has received FDA approval for its self-developed biosimilar HLX13, intended for the first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] Group 1 - The company plans to conduct an international multicenter clinical trial in the United States once conditions are met [1]